1-20 of 55
Francesco Bertoni
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 463: The small nucleolar RNA SNORD46 and SNORD72 have tumor suppressor activity in diffuse large B cell lymphoma

Elaine YL Chung, Filippo Spriano, Sara Napoli, Giulio Sartori, Luciano Cascione, Francesco Bertoni
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 463.
https://doi.org/10.1158/1538-7445.AM2024-463
Published: 22 March 2024
View article titled, Abstract 463: The small nucleolar RNA SNORD46 and SNORD72 have tumor suppressor activity in diffuse large B cell lymphoma
Journal Articles

Abstract 534: Novel marginal zone lymphoma models of resistance to the dual inhibition of PI3K and BCL2

Alberto J. Arribas, Luciano Cascione, Eleonora Cannas, Helen Bellerjeau, Federica Fuzio, Aleix Noguera, Andrea Rinaldi, Manel Esteller, Emanuele Zucca, Andrea Alimonti, Davide Rossi, Anastasios Stathis, Francesco Bertoni
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 534.
https://doi.org/10.1158/1538-7445.AM2024-534
Published: 22 March 2024
View article titled, Abstract 534: Novel marginal zone lymphoma models of resistance to the dual inhibition of PI3K and BCL2
Journal Articles

Abstract 2721: FF01: a novel humanized heavy chain antibody targeting endogenous retroviruses with anti-lymphoma activity

Filippo Spriano, Luciano Cascione, Jacopo Sgrignani, Nikolai Bendik, Sara Napoli, Giulio Sartori, Eleonora Cannas, Tao Gongo, Alberto J. Arribas, Davide Rossi, Davide F. Robbiani, Andrea Cavalli, Francesco Bertoni
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 2721.
https://doi.org/10.1158/1538-7445.AM2024-2721
Published: 22 March 2024
View article titled, Abstract 2721: FF01: a novel humanized heavy chain antibody targeting endogenous retroviruses with anti-lymphoma activity
Journal Articles

Abstract 7140: A new series of flavonoid derivatives with anti-cancer activity includes SDN207, SND210, SND524, and SND562 as potent microtubule-targeting agents

Alberto J. Arribas, Eleonora Cannas, Eugenio Gaudio, Paulina Biniecka, Dan Stoicescu, Francesco Bertoni
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 7140.
https://doi.org/10.1158/1538-7445.AM2024-7140
Published: 22 March 2024
View article titled, Abstract 7140: A new series of flavonoid derivatives with anti-cancer activity includes SDN207, SND210, SND524, and SND562 as potent microtubule-targeting agents
Journal Articles

Abstract 5836: CRISPR/Cas9 screening identifies genes affecting the sensitivity to the copanlisib/venetoclax combination in lymphoma cells

Sara Napoli, Alberto J. Arribas, Eleonora Cannas, Federica Fuzio, Luciano Cascione, Andrea Rinaldi, Emanuele Zucca, Andrea Alimonti, Anastasios Stathis, Francesco Bertoni
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 5836.
https://doi.org/10.1158/1538-7445.AM2024-5836
Published: 22 March 2024
View article titled, Abstract 5836: CRISPR/Cas9 screening identifies genes affecting the sensitivity to the copanlisib/venetoclax combination in lymphoma cells
Journal Articles

Abstract 394: ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms

Alberto J. Arribas, Sara Napoli, Luciano Cascione, Laura Barnabei, Giulio Sartori, Eleonora Cannas, Eugenio Gaudio, Chiara Tarantelli, Afua A. Mensah, Filippo Spriano, Antonella Zucchetto, Francesca M. Rossi, Andrea Rinaldi, Manuel Castro de Moura, Anastasios Stathis, Georg Stussi, Valter Gattei, Jennifer R. Brown, Manel Esteller, Emanuele Zucca, Davide Rossi, Francesco Bertoni
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 394.
https://doi.org/10.1158/1538-7445.AM2023-394
Published: 04 April 2023
View article titled, Abstract 394: ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms
Journal Articles

Abstract 492: Pharmacological inhibition of CXCR4 increases the anti-tumor activity of conventional and targeted therapies in B cell lymphoma models

Laura Barnabei, Alberto J. Arribas, Luciano Cascione, Francesca Guidetti, Filippo Spriano, Chiara Tarantelli, Andrea Rinaldi, Anastasios Stathis, Davide Rossi, Emanuele Zucca, Johann Zimmermann, Francesco Bertoni
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 492.
https://doi.org/10.1158/1538-7445.AM2023-492
Published: 04 April 2023
View article titled, Abstract 492: Pharmacological inhibition of CXCR4 increases the anti-tumor activity of conventional and targeted therapies in B cell lymphoma models
Journal Articles

Abstract 1817: EG-011 is a first-in-class Wiskott-Aldrich syndrome protein (WASp) activator with anti-tumor activity

Filippo Spriano, Laura Barnabei, Ana Maria Carrasco Del Amor, Meagan R. Tomasso, Chiara Tarantelli, Eugenia Riveiro, Natalina Pazzi, Shae B. Padrick, Susana Cristobal, Franco Cavalli, Eugenio Gaudio, Francesco Bertoni
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1817.
https://doi.org/10.1158/1538-7445.AM2022-1817
Published: 15 June 2022
View article titled, Abstract 1817: EG-011 is a first-in-class Wiskott-Aldrich syndrome protein (WASp) activator with anti-tumor activity
Journal Articles

Abstract 3279: Dual inhibition of EZH2 and histone deacetylases for the treatment of lymphomas with epigenetic aberrations

Afua Adjeiwaa Mensah, Sergio Valente, Milos Matkovic, Giulio Sartori, Chiara Falzarano, Chiara Tarantelli, Luciano Cascione, Stefano A. Pileri, Andrea Cavalli, Antonello Mai, Francesco Bertoni
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 3279.
https://doi.org/10.1158/1538-7445.AM2022-3279
Published: 15 June 2022
View article titled, Abstract 3279: Dual inhibition of EZH2 and histone deacetylases for the treatment of lymphomas with epigenetic aberrations
Journal Articles

Abstract 1879: A novel implantable device to in vivo assess anti-cancer agents

Giuseppe Perale, Eugenio Gaudio, Tommaso Casalini, Luca Aresu, Anna Rita De Corso, Filippo Spriano, Chiara Tarantelli, Anastasios Stathis, Andrea Castrovinci, Francesco Bertoni
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1879.
https://doi.org/10.1158/1538-7445.AM2022-1879
Published: 15 June 2022
View article titled, Abstract 1879: A novel implantable device to <em>in vivo</em> assess anti-cancer agents
Journal Articles

Abstract 3942: Novel BCL2 inhibitors with anti-lymphoma activity

Afua Adjeiwaa Mensah, Christos M. Chatzigiannis, Dimitrios A. Diamantis, Vasileios K. Gkalpinos, Alberto Arribas, Andreas G. Tzakos, Francesco Bertoni
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 3942.
https://doi.org/10.1158/1538-7445.AM2022-3942
Published: 15 June 2022
View article titled, Abstract 3942: Novel BCL2 inhibitors with anti-lymphoma activity
Journal Articles

Abstract 2655: The GPCR OR13A1 is essential for lymphoma cells

Giulio Sartori, Luciano Cascione, Milos Matkovic, Hiroaki Matsunami, Andrea Cavalli, Francesco Bertoni
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 2655.
https://doi.org/10.1158/1538-7445.AM2022-2655
Published: 15 June 2022
View article titled, Abstract 2655: The GPCR OR13A1 is essential for lymphoma cells
Journal Articles

Abstract 2575: Avanbulin, the active moiety of the tumor checkpoint controller lisavanbulin (BAL101553), has anti-lymphoma activity

Filippo Spriano, Luca Aresu, Luciano Cascione, Alberto J. Arribas, Nicole Forster-Gross, Felix Bachmann, Heidi Lane, Francesco Bertoni
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 2575.
https://doi.org/10.1158/1538-7445.AM2022-2575
Published: 15 June 2022
View article titled, Abstract 2575: Avanbulin, the active moiety of the tumor checkpoint controller lisavanbulin (BAL101553), has anti-lymphoma activity
Journal Articles

Abstract 163: DNA methyltransferase modulation in lymphoma cells involves functional redundancy and maintains hypermethylation of selected regions

Raffaele Frazzi, Vincenza Ylenia Cusenza, Luciano Cascione, Andrea Rinaldi, Francesco Bertoni, Mariaelena Pistoni, Francesco Merli
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 163.
https://doi.org/10.1158/1538-7445.AM2020-163
Published: 15 August 2020
View article titled, Abstract 163: DNA methyltransferase modulation in lymphoma cells involves functional redundancy and maintains hypermethylation of selected regions
Journal Articles

Abstract 4206: EUD-GK-001 is a novel kinase inhibitor with in vitro anti-lymphoma activity

Lorenzo Scalise, Chiara Tarantelli, Fabio Zuccotto, Filippo Spriano, Michele Mascia, Luciano Cascione, Eugenio Gaudio, Mauro Angiolini, Francesco Bertoni
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 4206.
https://doi.org/10.1158/1538-7445.AM2020-4206
Published: 15 August 2020
View article titled, Abstract 4206: EUD-GK-001 is a novel kinase inhibitor with <em>in vitro</em> anti-lymphoma activity
Journal Articles

Abstract 5215: Inhibition of PIM kinases targets synthetic vulnerabilities and enhances antigen presentation in B cell lymphoma

Patrizia Mondello, Chiara Tarantelli, Luciano Cascione, Alberto J. Arribas, Andrea Rinaldi, Anas Younes, Francesco Bertoni
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 5215.
https://doi.org/10.1158/1538-7445.AM2020-5215
Published: 15 August 2020
View article titled, Abstract 5215: Inhibition of PIM kinases targets synthetic vulnerabilities and enhances antigen presentation in B cell lymphoma
Journal Articles

Abstract 274: The ATR inhibitor BAY 1895344 shows strong preclinical activity in lymphomas and appears associated with specific gene expression signatures

Eugenio Gaudio, Chiara Tarantelli, Filippo Spriano, Luciano Cascione, Alberto Arribas, Emanuele Zucca, Anastasios Stathis, Antje Margret Wengner, Francesco Bertoni
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 274.
https://doi.org/10.1158/1538-7445.AM2019-274
Published: 01 July 2019
View article titled, Abstract 274: The ATR inhibitor BAY 1895344 shows strong preclinical activity in lymphomas and appears associated with specific gene expression signatures
Journal Articles

Abstract 4735: The histone deacetylase inhibitor pracinostat modulates the transcriptome of diffuse large B-cell lymphoma cells and is active in combination with several targeted agents

Afua A. Mensah, Filippo Spriano, Eugenio Gaudio, Chiara Chiara Tarantelli, Luciano Cascione, Andrea Rinaldi, Emanuela Lovati, Emanuele Zucca, Anastasios Stathis, Claudio Pietra, Francesco Bertoni
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 4735.
https://doi.org/10.1158/1538-7445.AM2019-4735
Published: 01 July 2019
View article titled, Abstract 4735: The histone deacetylase inhibitor pracinostat modulates the transcriptome of diffuse large B-cell lymphoma cells and is active in combination with several targeted agents
Journal Articles

Abstract 4796: EG-011 is a novel small molecule with in vitro and in vivo anti-tumor activity against lymphoma

Eugenio Gaudio, Filippo Spriano, Chiara Tarantelli, Matilde Guala, Eugenia Riveiro, Gaetanina Golino, Antonio Lupia, Giosuè Costa, Roberta Rocca, Luciano Cascione, Silvia Jenni, Yi-Chien Tsai, Beat Bornhauser, Stefano Alcaro, Francesco Paduano, Francesco Trapasso, Emanuele Zucca, Anastasios Stathis, Natalina Pazzi, Franco Cavalli, Francesco Bertoni
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 4796.
https://doi.org/10.1158/1538-7445.AM2019-4796
Published: 01 July 2019
View article titled, Abstract 4796: EG-011 is a novel small molecule with <em>in vitro</em> and <em>in vivo</em> anti-tumor activity against lymphoma
Journal Articles

Abstract 3829: NEO1132 and NEO2734, novel dual bromodomain inhibitors of both BET and CREBBP/EP300, compared to single BET or CREBB/EP300 inhibitors in diffuse large B cell lymphoma

Filippo Spriano, Eugenio Gaudio, Chiara Tarantelli, Gaetanina Golino, Luciano Cascione, Emanuele Zucca, Anastasios Stathis, Francis Giles, Francesco Bertoni
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 3829.
https://doi.org/10.1158/1538-7445.AM2019-3829
Published: 01 July 2019
View article titled, Abstract 3829: NEO1132 and NEO2734, novel dual bromodomain inhibitors of both BET and CREBBP/EP300, compared to single BET or CREBB/EP300 inhibitors in diffuse large B cell lymphoma